Avantor fluid handling solutions help scale-up production of COVID-19 mRNA manufacturer
Processing challenges in realizing the future potential of mRNA vaccines and therapies
Messenger RNA (mRNA) vaccines and therapies have the potential to provide powerful clinical benefit beyond infectious disease – thanks to a simple, robust and scalable manufacturing process. mRNA vaccines use artificially created mRNA to “teach” cells to make a specific protein that triggers an immune response in the person who receives the treatment. Other mRNA therapeutics produce a protein to compensate for a defective or missing gene or protein.
Vaccines created this way were first approved during the COVID-19 pandemic, and Avantor® partnered with multiple customers to support the scale up to mass produce the vaccine. Customers appreciate our solutions-driven approach to optimize resources and improve productivity — reducing risk and cost during scale up.
With years of industry experience, backed by a globally integrated supply network, Avantor delivers a robust and scalable manufacturing process that is agile and efficient. We supply a wide range of quality cGMP chemicals and reagents, chromatography resins, and aseptic fluid handling solutions to help researchers and manufacturers quickly move biologics from research to reality.
Choose Avantor for the expert support needed to simplify manufacturing process steps and manage your equipment and information system needs — so you have more time to focus on developing new therapies quickly and safely.
mRNA vaccine and therapy manufacturing
Avantor collaborates to develop customized solutions that reduce waste and increase flexibility and agility to meet capacity demands.
Plasmid manufacturing
Plasmid DNA (pDNA) is the starting point of mRNA vaccines and therapies, and its design and purity are critical to optimizing therapeutics. Avantor provides a wide range of high performance salts, buffers and reagents, as well as Avantor J.T.Baker® brand BAKERBOND® chromatography resins, which are essential to the production and isolation of high purity pDNA.
In vitro transcription
In vitro transcription (IVT), the enzymatic conversion of pDNA to mRNA, is the most critical step in mRNA vaccine and therapy production. The enzymes used in this process require optimal buffer conditions for the reaction to occur. Avantor supplies high purity cGMP reagents, such as dithiothreitol, magnesium chloride, Tris HCL, and sodium chloride, which are well characterized and mitigate the risk of impurity contamination during mRNA production.
mRNA purification
Following the IVT reaction, the mRNA product must be purified through chromatography. Avantor J.T.Baker® brand BAKERBOND® reverse phase and anion exchange chromatography resins give your mRNA vaccine and therapy production teams the ability to eliminate impurities during this step in the process. Avantor associates' expertise in chromatography resins, together with our wide offering of buffers, salts and reagents, delivers a quality final product that meets your exact specifications and speed to market demands.
Formulation, fill and finish
The most common formulation for mRNA vaccines and therapies is lipid nanoparticle (LNP) encapsulation. Cholesterol is a vital component of LNPs and maintains LNP stability — facilitating cellular intake. Avantor supplies a wide range of buffers, sugars, salts and surfactants that prevent mRNA degradation during manufacturing and handling. These products also improve the stability of mRNA vaccines and therapies, prolonging shelf life. Additionally, we offer packaging materials, such as vials and stoppers, that meet stringent internal and external quality requirements.
Fluid handling for mRNA vaccines and therapies
Avantor can support every stage of your mRNA vaccine and therapy production process with end-to-end fluid handling solutions. This includes tubing, connectors, assemblies and pumps for aseptic fluid handling and storage across all stages of your workflow. Additionally, Avantor buffer management optimization strategies enable manufacturers to reduce facility footprint, equipment cost, and labor requirements by providing hydrated, premade liquid buffers and buffer concentrates.
mRNA: Advancing vaccine technology
Partnering with Avantor adds reliability and agility in mRNA vaccines and therapy production process. Our global network offers end-to-end support – keeping us ready for when the world needs science.
mRNA vaccine & therapy products
Optimize your workflow with our innovative mRNA therapy products and solutions. Avantor provides compliant materials that include:
- Plasmid DNA production products
- Cell culture media and sera
- High performance salts, buffers and reagents
- Expansion and purification chemicals
- Quality packaging materials
- Single-use fluid connectivity, sampling and sterile transfer
We also offer tailored innovative solutions to help you solve process challenges. These include:
- Customized single-use solutions
- Custom-packaged buffers and excipients
- Customized formats for media, sterile solutions, excipients and preservation reagents
Explore our portfolio of cGMP chemicals, single-use solutions, sera and more on vwr.com
Explore our biomanufacturing products
Start optimizing your process performance with our innovative products and single-use solutions for mRNA vaccines and therapies production:
